Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 90 matching trials from the live ClinicalTrials.gov search.
Conditions
Psoriasis
Interventions
CEP-701 20mg, CEP-701 40mg, CEP-701 60mg, CEP-701 80mg
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Dallas, Texas • Norfolk, Virginia
Conditions
Psoriasis
Interventions
XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more
Conditions
Psoriasis
Interventions
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab 150 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more
Conditions
Chronic Plaque Psoriasis
Interventions
E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Hot Springs, Arkansas • San Diego, California • Boise, Idaho + 9 more
Conditions
Plaque-type Psoriasis
Interventions
COL-121, 50 µg/g Calcipotriene Ointment, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 17 more
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
20
States / cities
Fresno, California • Los Angeles, California • Redwood City, California + 16 more
Conditions
Psoriasis
Interventions
ustekinumab, placebo
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more
Conditions
Psoriasis
Interventions
Placebo, SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
St Louis, Missouri • New York, New York • Portland, Oregon + 4 more
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
AIN457 150mg, AIN457 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Fresno, California • Pasadena, California • Sacramento, California + 28 more
Conditions
Psoriasis
Interventions
Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Conditions
Psoriasis
Interventions
Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
Conditions
Psoriasis
Interventions
U0267, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Miami, Florida + 9 more
Conditions
Chronic Plaque Psoriasis
Interventions
AIN457, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more
Conditions
Palmoplantar Psoriasis, Plaque Psoriasis
Interventions
Duobrii®
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Plaque Type Psoriasis
Interventions
AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Conditions
Psoriasis
Interventions
Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more
Conditions
Psoriasis
Interventions
Bicillin L-A
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Plaque-type Psoriasis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more
Conditions
Psoriasis
Interventions
risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
79
States / cities
Birmingham, Alabama • Rogers, Arkansas • Bakersfield, California + 65 more
Conditions
Chronic Plaque-type Psoriasis
Interventions
CJM112, Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Anniston, Alabama • Anaheim, California • Encino, California + 14 more
Conditions
Psoriasis, Plaque-type
Interventions
Thalidomide oral
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Psoriasis
Interventions
Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
26
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 23 more